High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research

Ying-Hong Shi²  Jia Fan¹  Zhi Dai²  Shuang-Jian Qiu²  Jian Zhou¹  Yuan-Fei Peng²  Ying-Hao Shen²  Zhen-Bin Ding²  Liu-Xiao Yang²  Lei Jin²  Meng-Xin Tian²  Wei-Ren Liu² 

[1] Institutes of Biomedical Sciences, Fudan University, Shanghai, People’s Republic of China;Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Zhongshan Hospital, Fudan University, 180 FengLin Road, Shanghai, China

关键词: Prognosis;    Immunohistochemistry;    Hepatocellular carcinoma;    Isocitrate dehydrogenase 2;    5-hydroxymethylcytosine;   

Others  :  804058
DOI  :  10.1186/1756-9966-33-32

 received in 2014-03-07, accepted in 2014-03-27,  发布年份 2014

【 摘 要 】

Background

The expression of 5-hydroxymethylcytosine (5-hmC) and isocitrate dehydrogenase 2 (IDH2) is frequently downregulated in numerous cancers. 5-hmC and IDH2 expression in hepatocellular carcinoma (HCC) has yet to be determined.

Methods

The immunohistochemical expression of 5-hmC and IDH2 were analyzed in tissue microarrays containing samples from 646 patients who had undergone hepatectomy for histologically proven HCC. The prognostic value of 5-hmC and IDH2 were evaluated by Cox regression and Kaplan-Meier analyses.

Results

We discovered that low 5-hmC and IDH2 expression was associated with malignant behaviors. Low 5-hmC or IDH2 expression alone and combined 5-hmC and IDH2 expression were associated with lower overall survival (OS) rates and higher cumulative recurrence rates. Multivariate analysis indicated that 5-hmC or IDH2 and 5-hmC/IDH2 were independent prognostic indicators for OS and time to recurrence (TTR), which was confirmed in an independent validation cohort.

Conclusions

5-hmC and IDH2 correlate with less aggressive tumor behavior in HCC. When 5-hmC and IDH2 are considered together, they serve as a prognostic marker in patients with surgically resected HCCs.

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011, 365:1118-1127.
• [2]Maluccio M, Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012, 62:394-399.
• [3]Rodriguez-Paredes M, Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.
• [4]Liu WR, Shi YH, Peng YF, Fan J: Epigenetics of hepatocellular carcinoma: a new horizon. Chin Med J 2012, 125:2349-2360.
• [5]Berdasco M, Esteller M: Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010, 19:698-711.
• [6]Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, Cao Y: Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res 2013, 32:96. BioMed Central Full Text
• [7]Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
• [8]Kriaucionis S, Heintz N: The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324:929-930.
• [9]Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y: Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
• [10]Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H: Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 2010, 38:e181.
• [11]Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146.
• [12]Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG: Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PloS One 2012, 7:e41036.
• [13]Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H, Koike K: Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 2012, 103:670-676.
• [14]Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y: Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32:663-669.
• [15]Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, Krex D, Lu Q, Pfeifer GP: 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011, 71:7360-7365.
• [16]Chen ML, Shen F, Huang W, Qi JH, Wang Y, Feng YQ, Liu SM, Yuan BF: Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry. Clin Chem 2013, 59:824-832.
• [17]Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H: Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 2011, 108:3270-3275.
• [18]Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S: Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013, 340:622-626.
• [19]Lokody I: Metabolism: IDH2 drives cancer in vivo. Nat Rev Cancer 2013, 13:756-757.
• [20]Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH: Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 2012, 107:643-650.
• [21]Wang Z, Bao Z, Yan W, You G, Wang Y, Li X, Zhang W: Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. J Exp Clin Cancer Res 2013, 32:59. BioMed Central Full Text
• [22]Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
• [23]Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593.
• [24]Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW, Cai XY, Zhou J, Cheng YF, Fan J, Qiu SJ: High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res 2013, 32:3. BioMed Central Full Text
• [25]Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, Ren N, Zhuang PY, Zhu XD, Fan J, Tang ZY: Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007, 47:684-690.
• [26]Shi YH, Ding WX, Zhou J, He JY, Xu Y, Gambotto AA, Rabinowich H, Fan J, Yin XM: Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 2008, 48:497-507.
• [27]Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, Dai Z, Shi GM, Wang XY, Ke AW, Wu B, Fan J: Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res 2008, 68:9167-9175.
• [28]Tsukada T, Fushida S, Harada S, Terai S, Yagi Y, Kinoshita J, Oyama K, Tajima H, Fujita H, Ninomiya I, Fujimura T, Ohta T: Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer. J Exp Clin Cancer Res 2011, 30:107. BioMed Central Full Text
• [29]Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M: Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
• [30]Zhang C, Moore LM, Li X, Yung WK, Zhang W: IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 2013, 15:1114-1126.
• [31]Wang JH, Chen WL, Li JM, Wu SF, Chen TL, Zhu YM, Zhang WN, Li Y, Qiu YP, Zhao AH, Mi JQ, Jin J, Wang YG, Ma QL, Huang H, Wu DP, Wang QR, Li Y, Yan XJ, Yan JS, Li JY, Wang S, Huang XJ, Wang BS, Jia W, Shen Y, Chen Z, Chen SJ: Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A 2013, 110:17017-17022.
• [32]Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM: IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011, 224:334-343.
• [33]Sia D, Tovar V, Moeini A, Llovet JM: Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013, 32:4861-4870.
• [34]Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
• [35]You JS, Jones PA: Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012, 22:9-20.
• [36]Meacham CE, Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.